MGX financials

Metagenomi Therapeutics (MGX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.

MGX income statement, yearly

YearRevenueGross profitOperating incomeNet incomeEPS
2025$25.21M–-$96.01M-$87.87M-2.36
2024$52.30M–-$88.90M-$78.06M-2.36
2023$44.76M–-$78.49M-$68.25M-20.05